Related Experiment Video
Updated: May 9, 2026
08:20
MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
Published on: August 11, 2015
New paradigms for treatment-resistant depression.
Carlos Zarate1, Ronald S Duman, Guosong Liu
1Experimental Therapeutics & Pathophysiology Branch, Division of Intramural Research Program, National Institute of Mental Health, National Institutes of Health, and Department of Health and Human Services, Bethesda, Maryland, USA.
Annals of the New York Academy of Sciences
|July 24, 2013
Summary
Novel depression treatments targeting the glutamatergic system show promise. NMDA receptor antagonists and magnesium may reverse stress-induced neural changes, offering new hope beyond traditional SSRIs and SNRIs.
Area of Science:
- Neuroscience
- Psychiatry
- Pharmacology
Background:
- Clinical depression is a prevalent mental disorder with severe consequences, affecting 15% of the population.
- Current treatments, primarily targeting monoamine neurotransmitters (SSRIs, SNRIs), have limitations including slow onset and low efficacy.
- A significant unmet need exists for more effective depression therapies.
Purpose of the Study:
- To explore the role of the glutamatergic system in depression.
- To investigate the therapeutic potential of NMDA receptor antagonists and magnesium in depression treatment.
- To understand the mechanisms underlying novel depression treatments.
Main Methods:
- Review of research on glutamatergic pathways and depression.
- Analysis of studies on ketamine as an NMDA receptor antagonist.
- Examination of magnesium's role in neural plasticity and stress response.
Main Results:
- Glutamatergic pathways are significantly implicated in depression.
- NMDA receptor antagonists, like ketamine, show promising antidepressant effects.
- Magnesium homeostasis is linked to depression and stress pathways.
Conclusions:
- NMDA receptor antagonists and magnesium demonstrate potential for synaptic repair and reversing stress-induced neural changes.
- These findings open new avenues for developing innovative depression treatments.
- Targeting the glutamatergic system represents a paradigm shift in depression research.
Related Concept Videos
01:23Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
01:26Psychosis: Goals of Pharmacotherapy
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...
01:28Drug Therapy
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:25Cognitive Therapy
Cognitive therapy, pioneered by Aaron T. Beck in the 1960s, is a structured approach to addressing psychological distress by focusing on the influence of thoughts on emotions and behaviors. All cognitive therapies involve the basic assumption that human beings have control over their feelings, and that how individuals feel about something depends on how they think about it. Unlike psychoanalytic methods that delve into unconscious processes or humanistic approaches emphasizing...
01:24Treatment Strategies for Psychological Disorders
Treatment approaches for psychological disorders fall into three main categories: psychological, biological, and sociocultural. Each approach targets different aspects of mental health, requiring varying levels of education and training.
Psychological therapies focus on modifying emotions, thoughts, and behaviors through talking, interpreting, listening, rewarding, challenging, and modeling. Clinical psychologists, counselors, and social workers commonly practice psychotherapy. Clinical...
Psychological therapies focus on modifying emotions, thoughts, and behaviors through talking, interpreting, listening, rewarding, challenging, and modeling. Clinical psychologists, counselors, and social workers commonly practice psychotherapy. Clinical...